Scientific Reports (Mar 2022)

Gene methylation of CADM1 and MAL identified as a biomarker of high grade anal intraepithelial neoplasia

  • Samuel Phillips,
  • Kahli Cassells,
  • Suzanne M. Garland,
  • Dorothy A. Machalek,
  • Jennifer M. Roberts,
  • David J. Templeton,
  • Fengyi Jin,
  • I. Mary Poynten,
  • Richard J. Hillman,
  • Andrew E. Grulich,
  • Gerald L. Murray,
  • Sepehr N. Tabrizi,
  • Monica Molano,
  • Alyssa M. Cornall,
  • SPANC team

DOI
https://doi.org/10.1038/s41598-022-07258-5
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 11

Abstract

Read online

Abstract Human papillomavirus (HPV) is detected in up to 96% of anal squamous cell cancers, where screening programs needed. However, the best methodology is still undetermined. Host DNA methylation markers CADM1, MAL and miR124 have been identified in cervical disease, but not anal disease. Anal swabs varying by disease grade were assessed for DNA methylation of CADM1, MAL and miR124-2. Each marker was compared across disease grades, stratified by HPV and HIV status. Receiver operating characteristic curves identified the predictive value of significant gene candidates. CADM1 methylation was significantly higher in high-grade squamous intraepithelial lesions (HSIL) compared with low-grade (LSIL) (p = 0.005) or normal (p < 0.001) samples with 67.2% correctly identified as HSIL. MAL methylation was significantly (p = 0.002) increased in HSIL compared with LSIL in HIV positive participants with 79.8% correctly indicated as HSIL. Gene miR124-2, showed no difference between disease grades. Biomarkers with established diagnostic value in cervical disease have limited utility in the prediction of anal disease, with CADM1 identified as a marker with screening potential in a gay and bisexual men (GBM) population and MAL in HIV positive GBM population. New markers specific to the anal mucosa are required to improve triage of high-risk individuals.